BAARERSTRASSE 14, ZUG, V8
Provides Business Update and Reports Second Quarter 2026 Financial Results
Shareholders Approve CRISPR Therapeutics AG 2026 Stock Option Plan
Provides Business Update and Reports First Quarter 2026 Financial Results
Annual Report to Security Holders
Material Contracts, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sales of Equity Securities
Prices Upsized Convertible Senior Notes Offering
Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Other Events
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence